当前位置：科学网首页 > 小柯机器人 >详情
恢复期血浆治疗对重症COVID-19患者有效
作者：小柯机器人 发布时间：2020/9/16 15:52:14

美国西奈山伊坎医学院Nicole M. Bouvier小组发现，恢复期血浆治疗对重症COVID-19患者有效。相关论文于2020年9月15日在线发表在《自然—医学》杂志上。

研究人员表示，由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）是一种新型人类疾病，几乎没有有效的治疗方法。从COVID-19康复者捐赠的恢复性血浆是血液中的无细胞成分，其中包含抗体，包括特异性识别SARS-CoV-2的抗体。这些抗体在输给感染SARS-CoV-2的患者时被认为具有抗病毒作用，可以在患者自身产生体液免疫应答之前抑制病毒复制。当还在开发新的抗病毒药和疫苗时，来自康复者的病毒特异性抗体通常是新兴传染病的首个可用疗法，也是一种权宜之计。
 
研究人员评估了纽约市西奈山医院39例严重或有生命危险的COVID-19患者康复血浆疗法的有效性。输血后第14天的氧气需求量仅在17.9％的血浆接受者中发生恶化，在匹配对照者中的比例为28.8％（调整后的优势比（OR）为0.86； 95％置信区间（CI）为0.75– 0.98;卡方检验P值=0.025）。血浆接受者的生存率也得到了改善（危险比（HR）为0.34； 95％CI为0.13-0.89；卡方检验P=0.027）。恢复期血浆可能有效抵抗COVID-19，但需要更多的随机对照试验。
 
附：英文原文

Title: Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study

Author: Sean T. H. Liu, Hung-Mo Lin, Ian Baine, Ania Wajnberg, Jeffrey P. Gumprecht, Farah Rahman, Denise Rodriguez, Pranai Tandon, Adel Bassily-Marcus, Jeffrey Bander, Charles Sanky, Amy Dupper, Allen Zheng, Freddy T. Nguyen, Fatima Amanat, Daniel Stadlbauer, Deena R. Altman, Benjamin K. Chen, Florian Krammer, Damodara Rao Mendu, Adolfo Firpo-Betancourt, Matthew A. Levin, Emilia Bagiella, Arturo Casadevall, Carlos Cordon-Cardo, Jeffrey S. Jhang, Suzanne A. Arinsburg, David L. Reich, Judith A. Aberg, Nicole M. Bouvier

Issue&Volume: 2020-09-15

Abstract: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments1. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses2,3. Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed1,2. This retrospective, propensity score–matched case–control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score–matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75–0.98; chi-square test P value=0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13–0.89; chi-square test P=0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.

DOI: 10.1038/s41591-020-1088-9

Source: https://www.nature.com/articles/s41591-020-1088-9

期刊信息

Nature Medicine：《自然—医学》，创刊于1995年。隶属于施普林格·自然出版集团，最新IF：30.641
官方网址：https://www.nature.com/nm/
投稿链接：https://mts-nmed.nature.com/cgi-bin/main.plex